Literature DB >> 16421119

Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis.

T Kanesaka1, M Mori, T Hattori, T Oki, S Kuwabara.   

Abstract

BACKGROUND: Adhesion molecules and matrix metalloproteinases (MMPs) are known to be relevant to the ongoing development and disappearance of areas of demyelination in the white matter of the CNS of multiple sclerosis (MS) patients. This study examined whether serum matrix metalloproteinase-3 (MMP-3) levels correlate with disease activity in MS.
METHODS: Serum MMP-3 levels in 47 consecutive patients with relapsing-remitting MS were measured by immunoassay every 4 weeks over a 15 month period.
RESULTS: During the study period, 48 clinical relapses occurred. Serum MMP-3 levels within 1 month of relapse were significantly higher than during the remission phase. Sequential analysis showed that serum MMP-3 levels had increased transiently at the time of clinical relapse but returned to the normal range within a month.
CONCLUSIONS: Circulatory MMP-3 levels are correlated with disease activity in relapsing-remitting MS. This may contribute to the breakdown of the blood-brain barrier at the time of relapse.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421119      PMCID: PMC2077579          DOI: 10.1136/jnnp.2005.068619

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  32 in total

1.  Multiple sclerosis: elevated expression of matrix metalloproteinases in blood monocytes.

Authors:  M Kouwenhoven; V Ozenci; A Gomes; D Yarilin; V Giedraitis; R Press; H Link
Journal:  J Autoimmun       Date:  2001-06       Impact factor: 7.094

2.  Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta.

Authors:  V Ozenci; M Kouwenhoven; N Teleshova; M Pashenkov; S Fredrikson; H Link
Journal:  J Neuroimmunol       Date:  2000-08-01       Impact factor: 3.478

3.  Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.

Authors:  E Waubant; D E Goodkin; L Gee; P Bacchetti; R Sloan; T Stewart; P B Andersson; G Stabler; K Miller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

4.  Metalloproteinases and their tissue inhibitors in multiple sclerosis.

Authors:  V Ozenci; L Rinaldi; N Teleshova; D Matusevicius; P Kivisäkk; M Kouwenhoven; H Link
Journal:  J Autoimmun       Date:  1999-06       Impact factor: 7.094

5.  High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis.

Authors:  N T Cheung; P T Dawes; K V Poulton; W E Ollier; D J Taylor; D L Mattey
Journal:  J Rheumatol       Date:  2000-04       Impact factor: 4.666

6.  Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis.

Authors:  C Ribbens; B Andre; J M Jaspar; O Kaye; M J Kaiser; D De Groote; M G Malaise
Journal:  J Rheumatol       Date:  2000-04       Impact factor: 4.666

7.  Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions.

Authors:  J A Cossins; J M Clements; J Ford; K M Miller; R Pigott; W Vos; P Van der Valk; C J De Groot
Journal:  Acta Neuropathol       Date:  1997-12       Impact factor: 17.088

8.  Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

Authors:  M A Lee; J Palace; G Stabler; J Ford; A Gearing; K Miller
Journal:  Brain       Date:  1999-02       Impact factor: 13.501

9.  Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis.

Authors:  H Yamanaka; Y Matsuda; M Tanaka; W Sendo; H Nakajima; A Taniguchi; N Kamatani
Journal:  Arthritis Rheum       Date:  2000-04

10.  Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke.

Authors:  D C Anthony; B Ferguson; M K Matyzak; K M Miller; M M Esiri; V H Perry
Journal:  Neuropathol Appl Neurobiol       Date:  1997-10       Impact factor: 8.090

View more
  10 in total

1.  Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens.

Authors:  Kathryn Thrailkill; Gael Cockrell; Pippa Simpson; Cynthia Moreau; John Fowlkes; R Clay Bunn
Journal:  Clin Chem Lab Med       Date:  2006       Impact factor: 3.694

2.  Cleavage of myelin associated glycoprotein by matrix metalloproteinases.

Authors:  Elizabeth Milward; Kee Jun Kim; Arek Szklarczyk; Thien Nguyen; Giorgia Melli; Mamatha Nayak; Deepa Deshpande; Chantel Fitzsimmons; Ahmet Hoke; Douglas Kerr; John W Griffin; Peter A Calabresi; Katherine Conant
Journal:  J Neuroimmunol       Date:  2007-12-11       Impact factor: 3.478

Review 3.  Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.

Authors:  Ralf G Rempe; Anika M S Hartz; Björn Bauer
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-20       Impact factor: 6.200

4.  The Role of Matrix Metalloproteinase 3 and 9 in the Pathogenesis of Acute Neuroinflammation. Implications for Disease Modifying Therapy.

Authors:  Srdjan Ljubisavljevic; I Stojanovic; J Basic; S Vojinovic; D Stojanov; G Djordjevic; D Pavlovic
Journal:  J Mol Neurosci       Date:  2015-02-22       Impact factor: 3.444

Review 5.  The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis.

Authors:  Abbas Mirshafiey; Babak Asghari; Ghasem Ghalamfarsa; Farhad Jadidi-Niaragh; Gholamreza Azizi
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

6.  Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls.

Authors:  Steven P Luckman; Nils Erik Gilhus; Fredrik Romi
Journal:  Autoimmune Dis       Date:  2011-08-01

7.  Matrix metalloproteinase activity stimulates N-cadherin shedding and the soluble N-cadherin ectodomain promotes classical microglial activation.

Authors:  Katherine Conant; Stefano Daniele; P Lorenzo Bozzelli; Tsion Abdi; Amanda Edwards; Arek Szklarczyk; India Olchefske; David Ottenheimer; Kathleen Maguire-Zeiss
Journal:  J Neuroinflammation       Date:  2017-03-17       Impact factor: 8.322

Review 8.  Albumin and multiple sclerosis.

Authors:  Steven M LeVine
Journal:  BMC Neurol       Date:  2016-04-12       Impact factor: 2.474

Review 9.  Zinc in Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Authors:  Mikkel Bredholt; Jette Lautrup Frederiksen
Journal:  ASN Neuro       Date:  2016-06-09       Impact factor: 4.146

10.  Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls.

Authors:  Marc Pawlitzki; Julia Uebelhör; Catherine M Sweeney-Reed; Heike Stephanik; Juliane Hoffmann; Anke Lux; Dirk Reinhold
Journal:  Nutrients       Date:  2018-07-26       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.